The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ...

Tonmoy Sharma, a 61-year-old doctor from Guwahati has been arrested in the US over an alleged $149-million healthcare fraud.

Key Takeaways Teen prescriptions for Wegovy rose 50% in 2024But many still can’t access the medication due to cost or ...

Court filings give insight into why shooting suspect Louis Mangione might have targeted the UnitedHealthcare executive: "It checks every box." In other news: Hospital construction trends include AI; ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

CNBC’s Angelica Peebles sits down with Lilly’s Head of Oncology, Jake Van Naarden, to discuss what’s next in Lilly’s oncology ...

An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...